PubMed Health⌕ Search

Biomedical subjects

Ia A Sigidin

Publications and source records attributed to Ia A Sigidin.

At least 19 recordsLinked to original sources
PubMed1995

[A trial of the use of the preparation Arthrotec for treating rheumatic diseases].

A clinical trial of arthrotek (Searle) in 60 RA patients aged 16-77 years demonstrated its high anti-inflammatory activity in 47 of them. These patients have received a complete treatment course, 10 patients were not included in the overall estimations because of side affects (gastric pains and nausea) causing them to withdraw early in the treatment course, 3 patients were nonresponders. The responders experienced attenuation of joint pain, morning stiffness. Inflammation in some joints declined, the articular index decreased.

Adolescent↗
PubMed1993

[A comparative evaluation of the treatment results with cyclosporin A, methotrexate and azathioprine in rheumatoid arthritis patients (a preliminary report)].

In a randomized trial 43 patients with RA systemic manifestations received for 6 months immunodepressants: azathioprine, methotrexate and cyclosporin A (12.15 and 16 patients, respectively). Ten more patients resistant to immunodepressants were given cyclosporin A. The drugs were found to produce a positive effect on clinical symptoms and laboratory indices of the disease. Cyclosporin A is thought a basic immunodepressant without serious hematological or infectious complications. Occasionally it can be useful in failure of other immunodepressants administered to RA patients.

Arthritis, Rheumatoid↗
PubMed1990

[New approaches to local antirheumatic therapy].

Local antirheumatic therapy is viewed as an important component in the total system of the treatment of rheumatic diseases. Drug-induced synovectomy, local anti-inflammatory, antifibrotic and potential immunosuppressive therapy are analyzed. Special attention is paid to local therapy based on the use of dimethyl sulfoxide. The effects of local and general treatment are realized at least partially by means of the same mechanisms. There is possibility to improve the results of general therapy at the expense of goal-oriented local treatment without producing any influence on its tolerance. In fact, every patient with rheumatoid arthritis or other articular disease should be regarded as a potential candidate for local anti-inflammatory therapy.

Administration, Topical↗
PubMed1989

[Effectiveness of intra-articular dimexide in combination with hydrocortisone and hydrocortisone in patients with juvenile rheumatoid arthritis].

A course of 4-5 intra-articular injections was given to 25 children aged 4-15 years with juvenile rheumatoid arthritis: 20% dimexide++ solution in combination with hydrocortisone (2 ml) was administered into the right knee joint and hydrocortisone (12.5 mg) into the left knee joint once a week. Dimexide++ solution combination with hydrocortisone proved to be most effective: all signs of inflammation subsided, the joint function was restored and there were no untoward reactions.

Arthritis, Juvenile↗
PubMed1988

[Piroxicam in the treatment of rheumatoid arthritis].

Open and double blind trials in 80 patients with proved and definite rheumatoid arthritis have shown that piroxicam possesses marked analgesic and antiinflammatory action, is well tolerated producing a therapeutic effect only at high doses exceeding the mean ones recommended in the literature.

Adult↗
PubMed1987

[New basic preparations with prolonged action in the treatment of rheumatoid arthritis].

A long-term comparative study of the classic basic drug-d-Penicillamin and 2 new sulfa drugs: sulfasalazin and salazopyridazin used for the first time in rheumatology, was conducted. Both drugs were shown to produce a "basic" effect in rheumatoid arthritis and to exceed d-Penicillamin in their therapeutic action. Better results were obtained with salazopyridazin. The tolerance to the new antirheumatic sulfa drugs was quite satisfactory; no severe side-effects were noted. Both drugs extend the potentialities of antirheumatoid therapy of prolonged action and warrant further use and study.

Adult↗
PubMed1987

[A new non-steroidal anti-inflammatory drug pirprofen (rengasil) in the treatment of rheumatoid arthritis and osteoarthrosis].

The results of a double blind clinical study of pirprofen, as compared to piroxicam and placebo in 197 patients with rheumatoid arthritis, as compared to piroxicam in 200 patients with gonarthrosis and/or coxarthrosis, and as compared to naproxen in 165 patients with lumbar spondylosis, are reviewed. In rheumatoid arthritis, pirprofen (1200 mg daily) was significantly superior to placebo, and proved in some respects more active than piroxicam where its daily dose was 20 mg. In patients with osteo-arthrosis affecting major joints and the spine, pirprofen (800 mg daily) showed the same therapeutic effects as piroxicam (20 mg) and naproxen (1000 mg). Owing to its obvious anti-inflammatory effect and good tolerance, pirprofen merits large-scale use in rheumatology.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed1987

[Comparative effectiveness of chrysanol and auranofin in rheumatoid arthritis].

A randomized study of 46 patients with classic and definite rheumatoid arthritis on chrysotherapy (25 patients--auranofin orally and 21--allochrysine intramuscularly) showed a therapeutic effect of both drugs. Allochrysine turned out more effective, it was not abandoned in any patients as a result of its inefficacy. However as compared to allochrysine auranofin was slightly better tolerated.

Administration, Oral↗
PubMed1987

[Herpes zoster--an unusual complication of gold therapy].

The authors observed the development of herpes zoster in 2 rheumatoid arthritic patients against a background of chrysanol therapy. Such a complication should be regarded as an indication for aurum drug cancellation. The study provided an opportunity for specifying some aspects in the mechanism of action and indicated a possible immunodepressive effect.

Arthritis, Rheumatoid↗